IL6R and ovarian carcinoma: Indeed, targeted anti-IL-6 antibody therapy has been used in clinical trials and found to be well tolerated in patients of several cancers, including ovarian cancer.[7] Tocilizumab (Chugai Pharmaceutical, Shizuoka, Japan), is a humanized anti-human IL-6R antibody and binds to the IL-6-binding site of human IL-6R.